Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)
出版年份 2015 全文链接
标题
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume 138, Issue 3, Pages 739-746
出版商
Wiley
发表日期
2015-08-19
DOI
10.1002/ijc.29807
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
- (2014) Lee S. Schwartzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
- (2013) Ching-Wen Huang et al. BMC CANCER
- Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
- (2013) George Pentheroudakis et al. BMC CANCER
- Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial
- (2013) C Giessen et al. BRITISH JOURNAL OF CANCER
- Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
- (2013) D J Jonker et al. BRITISH JOURNAL OF CANCER
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis
- (2013) Jens Neumann et al. VIRCHOWS ARCHIV
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
- (2012) S. Stintzing et al. ANNALS OF ONCOLOGY
- Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases
- (2012) Hidekazu Kuramochi et al. BMC CANCER
- Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
- (2012) X. Liao et al. CLINICAL CANCER RESEARCH
- A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies
- (2012) Michihiro Yoshida et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
- (2011) J B Baker et al. BRITISH JOURNAL OF CANCER
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
- (2010) Jolien Tol et al. EUROPEAN JOURNAL OF CANCER
- Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
- (2010) Ludwig Fischer von Weikersthal et al. EUROPEAN JOURNAL OF CANCER
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2009) Bart Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
- (2009) Jens Neumann et al. PATHOLOGY RESEARCH AND PRACTICE
- Amphiregulin Is a Promising Prognostic Marker for Liver Metastases of Colorectal Cancer
- (2008) M. Yamada et al. CLINICAL CANCER RESEARCH
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation